跳至主要内容
临床试验/KCT0003789
KCT0003789招募中未知

A multi-center and non-interventional registry of Brentuximab Vedotin in patients with relapsed or refractory anaplastic large cell lymphoma or classical Hodgkin lymphoma

Samsung Medical Center0 个研究点目标入组 150 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational Study

入排标准

年龄范围
o Limit 至 o Limit(—)
性别
All

入选标准

  • 1) Any patient planning to administer BrentuximabVedotin to treat the target disease.
  • 2) Any patient administering BrentuximabVedotin to treat the target disease.
  • 3) Any patient tracing BrentuximabVedotin after treating the target disease.
  • 4) Any patient administering another salvage option for cancer as the target disease has relapsed after terminating treatment using BrentuximabVedotin

排除标准

  • If conditions for target diseases are not met.
  • If conditions for target patients are not met.
  • If patients do not give written consent to participate in study.

研究者

相似试验